Development of auto antigen-specific regulatory T cells for diabetes immunotherapy

Jianxun Song

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

CD4+ regulatory T cells (Tregs) are essential for normal immune surveillance, and their dysfunction can lead to the development of autoimmune diseases, such as type-1 diabetes (T1D). T1D is a T cell-mediated autoimmune disease characterized by islet b cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. Tregs play a critical role in the development of T1D and participate in peripheral tolerance. Pluripotent stem cells (PSCs) can be utilized to obtain a renewable source of healthy Tregs to treat T1D as they have the ability to produce almost all cell types in the body, including Tregs. However, the right conditions for the development of antigen (Ag)-specific Tregs from PSCs (i.e., PSC-Tregs) remain undefined, especially molecular mechanisms that direct differentiation of such Tregs. Auto Ag-specific PSC-Tregs can be programmed to be tissue-associated and infiltrate to local inflamed tissue (e.g., islets) to suppress autoimmune responses after adoptive transfer, thereby avoiding potential overall immunosuppression from non-specific Tregs. Developing auto Ag-specific PSC-Tregs can reduce overall immunosuppression after adoptive transfer by accumulating inflamed islets, which drives forward the use of therapeutic PSC-Tregs for cell-based therapies in T1D.

Original languageEnglish (US)
Pages (from-to)281-285
Number of pages5
JournalImmune Network
Volume16
Issue number5
DOIs
StatePublished - Jan 1 2016

Fingerprint

Pluripotent Stem Cells
Regulatory T-Lymphocytes
Immunotherapy
Type 1 Diabetes Mellitus
Antigens
Adoptive Transfer
Immunosuppression
Autoimmune Diseases
Peripheral Tolerance
Therapeutic Uses
Cell- and Tissue-Based Therapy
Autoimmunity
Islets of Langerhans
Homeostasis
T-Lymphocytes
Glucose

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

@article{f5846f8cbb81422db32b398d2e93f27d,
title = "Development of auto antigen-specific regulatory T cells for diabetes immunotherapy",
abstract = "CD4+ regulatory T cells (Tregs) are essential for normal immune surveillance, and their dysfunction can lead to the development of autoimmune diseases, such as type-1 diabetes (T1D). T1D is a T cell-mediated autoimmune disease characterized by islet b cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. Tregs play a critical role in the development of T1D and participate in peripheral tolerance. Pluripotent stem cells (PSCs) can be utilized to obtain a renewable source of healthy Tregs to treat T1D as they have the ability to produce almost all cell types in the body, including Tregs. However, the right conditions for the development of antigen (Ag)-specific Tregs from PSCs (i.e., PSC-Tregs) remain undefined, especially molecular mechanisms that direct differentiation of such Tregs. Auto Ag-specific PSC-Tregs can be programmed to be tissue-associated and infiltrate to local inflamed tissue (e.g., islets) to suppress autoimmune responses after adoptive transfer, thereby avoiding potential overall immunosuppression from non-specific Tregs. Developing auto Ag-specific PSC-Tregs can reduce overall immunosuppression after adoptive transfer by accumulating inflamed islets, which drives forward the use of therapeutic PSC-Tregs for cell-based therapies in T1D.",
author = "Jianxun Song",
year = "2016",
month = "1",
day = "1",
doi = "10.4110/in.2016.16.5.281",
language = "English (US)",
volume = "16",
pages = "281--285",
journal = "Immune Network",
issn = "1598-2629",
publisher = "Korean Association of Immunologists",
number = "5",

}

Development of auto antigen-specific regulatory T cells for diabetes immunotherapy. / Song, Jianxun.

In: Immune Network, Vol. 16, No. 5, 01.01.2016, p. 281-285.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Development of auto antigen-specific regulatory T cells for diabetes immunotherapy

AU - Song, Jianxun

PY - 2016/1/1

Y1 - 2016/1/1

N2 - CD4+ regulatory T cells (Tregs) are essential for normal immune surveillance, and their dysfunction can lead to the development of autoimmune diseases, such as type-1 diabetes (T1D). T1D is a T cell-mediated autoimmune disease characterized by islet b cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. Tregs play a critical role in the development of T1D and participate in peripheral tolerance. Pluripotent stem cells (PSCs) can be utilized to obtain a renewable source of healthy Tregs to treat T1D as they have the ability to produce almost all cell types in the body, including Tregs. However, the right conditions for the development of antigen (Ag)-specific Tregs from PSCs (i.e., PSC-Tregs) remain undefined, especially molecular mechanisms that direct differentiation of such Tregs. Auto Ag-specific PSC-Tregs can be programmed to be tissue-associated and infiltrate to local inflamed tissue (e.g., islets) to suppress autoimmune responses after adoptive transfer, thereby avoiding potential overall immunosuppression from non-specific Tregs. Developing auto Ag-specific PSC-Tregs can reduce overall immunosuppression after adoptive transfer by accumulating inflamed islets, which drives forward the use of therapeutic PSC-Tregs for cell-based therapies in T1D.

AB - CD4+ regulatory T cells (Tregs) are essential for normal immune surveillance, and their dysfunction can lead to the development of autoimmune diseases, such as type-1 diabetes (T1D). T1D is a T cell-mediated autoimmune disease characterized by islet b cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. Tregs play a critical role in the development of T1D and participate in peripheral tolerance. Pluripotent stem cells (PSCs) can be utilized to obtain a renewable source of healthy Tregs to treat T1D as they have the ability to produce almost all cell types in the body, including Tregs. However, the right conditions for the development of antigen (Ag)-specific Tregs from PSCs (i.e., PSC-Tregs) remain undefined, especially molecular mechanisms that direct differentiation of such Tregs. Auto Ag-specific PSC-Tregs can be programmed to be tissue-associated and infiltrate to local inflamed tissue (e.g., islets) to suppress autoimmune responses after adoptive transfer, thereby avoiding potential overall immunosuppression from non-specific Tregs. Developing auto Ag-specific PSC-Tregs can reduce overall immunosuppression after adoptive transfer by accumulating inflamed islets, which drives forward the use of therapeutic PSC-Tregs for cell-based therapies in T1D.

UR - http://www.scopus.com/inward/record.url?scp=85018499271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018499271&partnerID=8YFLogxK

U2 - 10.4110/in.2016.16.5.281

DO - 10.4110/in.2016.16.5.281

M3 - Review article

C2 - 27799873

AN - SCOPUS:85018499271

VL - 16

SP - 281

EP - 285

JO - Immune Network

JF - Immune Network

SN - 1598-2629

IS - 5

ER -